• Hosted by GenSight Biologics (EPA:  SIGHT)
  • Date:  Wednesday July 7th, 2021
  • Time: 8:30 - 9:30 am CEST
The event will be webcast live in French only at https://bit.ly/36fQ9yO.

GenSight’s management team will host a webcast on Wednesday July 7, 2021 from 8:30 am to 9:30 am CEST in French and dedicated to retail investors about the Topline results from REFLECT Phase III Clinical Trial of LUMEVOQ® in the treatment of Leber Hereditary Optic Neuropathy (LHON) that GenSight reported on June 30, 2021..

Dr. José-Alain Sahel will attend and be available for questions.


Wednesday July 7, 2021

 You will need to register in advance to get access to both webcasts. For those unable to attend the live broadcast, a recording will be accessible using the same links.